Philippines To Set National R&D Priorities, But Regulations May Hamper Foreign Industry Support
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The Philippines government is formulating research priorities for the next five years, including health and biotechnology projects, to boost the country's research and development capabilities. But some industry observers warn that the country's desire to maintain drug prices through the use of steep price cuts will discourage foreign companies from participating in the country's life sciences development
You may also be interested in...
Government Emphasis On Preventative Care Needed To Curb Healthcare Costs in Asia
SHANGHAI - Creating incentives for people to lead a healthy lifestyle is one key to expanding access to healthcare in Asia, especially as the population ages and takes up more of limited national budgets, according to a recent report from global consulting firm Frost & Sullivan
Government Emphasis On Preventative Care Needed To Curb Healthcare Costs in Asia
SHANGHAI - Creating incentives for people to lead a healthy lifestyle is one key to expanding access to healthcare in Asia, especially as the population ages and takes up more of limited national budgets, according to a recent report from global consulting firm Frost & Sullivan
Coalition Blames Slow Judicial Process and Parallel Drug Importation Program For Fake Drugs In Philippines
SHANGHAI - The Coalition Against Fake Medicines, a group of multisectoral representatives in the healthcare industry, including pharmacists, retailers, and generics companies in the Philippines, recently called the country's slow judicial process a major factor in the rise of fake medicines, and said the government's parallel drug importation program under the Cheap Medicine Act partly helps counterfeits enter the country